Tafoxiparin Licensing Deal Faces EU Approval Uncertainty as Exeltis Awaits Market Authorization
Exeltis's semi-global license for tafoxiparin from Dilafor could become commercially worthless if the women's health drug fails to secure regulatory approval in key European markets. The pharmaceutical licensing agreement carries medium-likelihood catastrophic risk, with regulators yet to authorize the compound for commercial distribution across EU territories covered by the deal.
ViaNews Editorial Team (Europe)•